Healthy Volunteers Clinical Trial
Official title:
A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, & Food Effect of RO5024048 in Healthy Volunteers & in Patients With Chronic HCV Infection
This is an adaptive Phase I study to evaluate RO5024048 in the following groups:
- Healthy Volunteers (Part 1 - Single Ascending Dose Study) -Enrollment completed
- Hepatitis C virus (HCV) genotype 1 infected patients who have failed interferon therapy
(Part 2- Multiple Ascending Dose Study)-Enrollment Completed
- HCV genotype 1-infected patients who are treatment naive, to be dosed in combination
with PEG-IFN and RBV (Part 3 - Combination Dose Study)-Currently Enrolling
- HCV genotype 2-3 infected patients who have previously been treated with interferon but
who did not respond, to be dosed in combination with PEG-IFN and RBV (Part 3 -
Combination Dose Study)- Currently enrolling
The study aims to determine if RO5024048 is safe and well-tolerated in healthy people and in
people infected with hepatitis C virus. The amount of RO5024048 in the blood will be
measured during the study and the amount of hepatitis C virus in the blood after each dose
will also be measured.
During Part 3 of the study, RO5024048 will be given with PEG-IFN and RBV, two drugs
currently used and approved for the treatment of HCV.
Part 3: During Part 3 of the study, HCV gentoype 1-infected patients who are treatment-naive
(have not been treated for HCV) will be enrolled. Up to 75 patients (3 groups of 25) will be
dosed for 28 days with RO5024048, PEG-IFN, and RBV. The first dose of RO5024048 to be given
in Part 3 will be 500 mg BID, the second dose will be 1500 mg BID, and the third group will
be 1000 mg BID. Standard doses of PEG-IFN and RBV will be used during Part 3. Doses of
PEG-IFN and RBV will be modified if necessary.
An 4th group of 25 HCV genotype 2 or 3-infected patients who have been previously treated
with interferon but who did not respond will also be enrolle in part 3. The dose given to
this 4th group will be 1500 mg BID, in combination with standard doses of PEG-IFN and RBV.
Following 28 days of combination dosing with RO5024048, PEG-IFN, and RBV, patients will be
dosed an additional 28 days (through Day 56 of the study) with just PEG-IFN, and RBV. After
completing 56 days under this study, patients who participate in Part 3 will be optionally
enrolled into a standard of care protocol with PEG-IFN and RBV, to be conducted by Roche.
Patients who opt to enroll into the standard of care protocol will be given up to 40 weeks
of PEG-IFN and RBV.
The primary objective for Part 3 is to assess the safety, tolerability and pharmacokinetics
of RO5024048 in treatment-naive HCV Genotype 1-infected patients, and in non-responder HCV
Genotype 2/3-infected patients, after once or twice daily dosing in combination wtih PEG-IFN
and RBV for 28 days on an outpatient basis. The secondary objective of Part 3 (COMBO) is to
evaluate the short-term decrease in viral load in treatment-naive HCV Genotype 1-infected
patients, and in non-responder HCV Genotype 2/3-infected patients, after once or twice daily
dosing of RO5024048 in combination with PEG-IFN and RBV for 28 days.
Part 1 (closed for enrollment): Single ascending dose study
During Part 1, 5 escalating single oral doses of RO5024048 or placebo were given to 40
healthy volunteers, when fasted (have not eaten any food for at least 10 hours). The doses
given were 500 mg, 1500 mg, 4500 mg, 6000 mg, and 9000 mg. Another group of 6 volunteers was
given 1500 mg with food.
The primary objective of Part 1 was to assess the safety, tolerability, and pharmacokinetics
(amount of drug in the blood) of RO5024048 under fasting conditions. The secondary objective
of Part 1 was to explore the effect of food on the pharmacokinetics of RO5024048.
Part 2: (Closed for enrollment) Multiple ascending dose study
During Part 2 of the study, 40 HCV-genotype 1-infected patients were given
multiple-ascending oral doses of RO5024048 or placebo for 14 days. The doses given were 750
mg once daily, 1500 mg once daily, 750 mg twice daily, and 1500 mg twice daily.
The primary objective of Part 2 was to assess the safety, tolerability and pharmacokinetics
of RO5024048 in HCV Genotype 1-infected patients after daily or twice daily dosing for 14
days. The secondary objective was to evaluate the decrease in viral load in HCV Genotype
1-infected patients after daily or twice daily dosing of RO5024048 for 14 days
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |